CSL Seqirus, a division of CSL Limited, is the second-largest influenza vaccine company in the world. The company strives to be a transglobal pandemic preparedness partner and is also a major contributor to the global prevention and control of influenza. The company’s team of 3,000 employees helps it to maintain a presence in over 20 countries. As an employer, CSL Seqirus has offered full-time, hybrid remote jobs in the past. The company seeks team members who are excited about joining a team dedicated to protecting communities of people from the influenza virus.

Headquartered in Victoria, Australia, CSL Seqirus was founded in 2015 when bioCSL and Novartis joined forces. In 2021, the company signed a multi-year contract with the U.S. federal government to develop influenza vaccines. CSL Seqirus uses both egg- and cell-based production technologies and offers two different types of quadrivalent influenza vaccines, and it has commercialized a seasonal influenza vaccine for older adults. In addition to its global work, CSL Seqirus markets a range of specialty pharmaceutical products and vaccines in Australia and New Zealand, in addition to marketing antifever and Q fever vaccines. The company’s experience dates back to the deadly 1918 flu pandemic and has worked with global health partners to protect against influenza ever since.

CSL Seqirus, a division of CSL Limited, is the second-largest influenza vaccine company in the world. The company strives to be a transglobal pandemic preparedness partner and is also a major contributor to the global prevention and control of influenza. The company’s team of 3,000 employees helps it to maintain a presence in over 20 countries. As an employer, CSL Seqirus has offered full-time, hybrid remote jobs in the past. The company seeks team members who are excited about joining a team dedicated to protecting communities of people from the influenza virus.

Headquartered in Victoria, Australia, CSL Seqirus was founded in 2015 when bioCSL and Novartis joined forces. In 2021, the company signed a multi-year contract with the U.S. federal government to develop influenza vaccines. CSL Seqirus uses both egg- and cell-based production technologies and offers two different types of quadrivalent influenza vaccines, and it has commercialized a seasonal influenza vaccine for older adults. In addition to its global work, CSL Seqirus markets a range of specialty pharmaceutical products and vaccines in Australia and New Zealand, in addition to marketing antifever and Q fever vaccines. The company’s experience dates back to the deadly 1918 flu pandemic and has worked with global health partners to protect against influenza ever since.